Prostate cancer is the most common cancer diagnosed among American men, and causes more deaths annually among men than any other tumor except lung cancer. However, only a small proportion of prostate cancers diagnosed are ultimately lethal. A large majority of men found to have prostate cancer ultimately die of other causes, most commonly cardiovascular disease. All available treatments for prostate cancer (surgery, radiation therapy, hormonal therapy, and others) carry a risk of complications, side effects, and other impacts to the patient's long-term quality of life. Before making a decision regarding treatment for prostate cancer it is important to estimate the likelihood that a given tumor will recur after treatment, progress, and pose a threat to life.
Risk Assessment Methods
Risk Assessment systems are not intended to replace individualized clinician-patient decision making, but rather to provide a straightforward instrument for facilitating disease risk classification in clinical decision making and in future research.There are many approaches to risk assessment including the D'Amico classification, a variety of nomograms and the UCSF-CAPRA Score.
A really good lecture on evaluating PCa risk and picking the right treatment. For high risk cancers, Radical Prostatectomy is significantly better the IMRT Radiation.
Localized Prostate Cancer: Progress Toward Personalized Care
Published on Sep 18, 2014
(Visit: http://www.uctv.tv/)
There were 233,000 new cases of prostate cancer in the US last year.
The good news is that there has been 40% drop in age-adjusted prostate
cancer mortality since early 1990s. Dr. Matthew Cooperberg, Associate Professor of Urology at UCSF, talks about screening, treatment and risk
assessment. He also explains the concept of active surveillance.
Recorded on 07/22/2014. Series: "UCSF Osher Center for Integrative
Medicine presents Mini Medical School for the Public" [9/2014] [Health
and Medicine] [Show ID: 28503]
No comments:
Post a Comment